ATMI, Inc.
Thesis
ATMI has a solid annuity-like business model with significant cash reserves and growth potential in life sciences and semiconductor technology, making it an attractive investment at its current valuation.
Did it work?
The recorded -100% return is almost certainly a delisting artifact rather than a genuine wipeout: ATMI (Advanced Technology Materials) was acquired by Entegris in 2014 for $35.50 per share in cash (after divesting its LifeSciences unit), an outcome that would have delivered a positive premium to shareholders and validated the cash-rich, undervalued-takeover-candidate thesis. Because the provided price data shows a total loss while the likely real outcome was a buyout at a premium, and the time elapsed since the pitch is unknown, the verdict cannot be determined confidently from the data given.